Oncology papers
Pofolia’s corpus holds 73 papers from Oncology (2012–2026), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries (2021, 113,108 citations).
- The 20 papers listed have 525,875 citations between them.
- 19 of the 20 with a known journal quartile appeared in a Q1 journal.
- 17 have a free full text (open access).
- Most frequent journals: CA A Cancer Journal for Clinicians, American Journal of Nephrology, Breast Care.
- Published between 2012 and 2024.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
CA A Cancer Journal for Clinicians · 2021 · Q1 · SJR 104.00 · FWCI 7597.27 · 113,108 citations · Open access
In 2020, an estimated 19.3 million new cancer cases and 10.0 million deaths occurred globally, with female breast cancer becoming the most commonly diagnosed cancer, surpassing lung cancer.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians · 2018 · Q1 · SJR 104.00 · FWCI 4080.68 · 87,943 citations · Open access
The GLOBOCAN 2018 estimates project 18.1 million new cancer cases and 9.6 million deaths globally, with lung cancer being the most common and deadliest. Significant geographic variability exists, highlighting disparities in cancer burden.
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Breast Care · 2016 · Q2 · FWCI 1607.02 · 30,918 citations · Open access
Immune checkpoint inhibition, specifically blocking PD-1 and PD-L1, shows significant promise for treating breast cancer, particularly triple-negative subtypes, potentially leading to long-term disease control.
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
International Journal of Cancer · 2014 · Q1 · SJR 1.00 · FWCI 1052.41 · 29,085 citations · Open access
GLOBOCAN 2012 estimates reveal 14.1 million new cancer cases and 8.2 million deaths globally, with lung, breast, and colorectal cancers being the most frequently diagnosed.
Global cancer statistics, 2012
CA A Cancer Journal for Clinicians · 2015 · Q1 · SJR 104.00 · FWCI 1664.54 · 27,385 citations · Open access
In 2012, cancer caused 14.1 million new cases and 8.2 million deaths globally, with the burden increasingly shifting to less developed countries.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians · 2024 · Q1 · SJR 104.00 · FWCI 4333.94 · 23,693 citations · Open access
In 2022, nearly 20 million new cancer cases and 9.7 million deaths were estimated globally, with lung cancer being the most frequent and deadliest. These figures highlight a lifetime risk of approximately 1 in 5 for developing cancer.
Cancer statistics, 2019
CA A Cancer Journal for Clinicians · 2019 · Q1 · SJR 104.00 · FWCI 1515.30 · 21,001 citations · Open access
In 2019, the US is projected to see 1,762,450 new cancer cases and 606,880 deaths, continuing a trend of declining mortality rates.
Cancer statistics, 2022
CA A Cancer Journal for Clinicians · 2022 · Q1 · SJR 104.00 · FWCI 1693.45 · 18,245 citations · Open access
In 2022, the US is projected to see 1.9 million new cancer cases and 609,360 deaths, with lung cancer remaining the leading cause of death. While progress has stalled for breast and prostate cancers, lung cancer shows significant gains due to improved early detection and treatment.
Cancer statistics in China, 2015
CA A Cancer Journal for Clinicians · 2016 · Q1 · SJR 104.00 · FWCI 1021.77 · 18,020 citations · Open access
An estimated 4.29 million new cancer cases and 2.81 million deaths are projected for China in 2015, with lung cancer being the most common and deadliest. Rural residents face significantly higher cancer incidence and mortality rates compared to urban dwellers.
Cancer Statistics, 2021
CA A Cancer Journal for Clinicians · 2021 · Q1 · SJR 104.00 · FWCI 1334.95 · 17,440 citations · Open access
The US is projected to see 1.9 million new cancer cases and 608,570 deaths in 2021, with the overall cancer death rate declining 31% since 1991.
Cancer statistics, 2018
CA A Cancer Journal for Clinicians · 2018 · Q1 · SJR 104.00 · FWCI 1062.66 · 17,022 citations
In 2018, the US is projected to see 1.735 million new cancer cases and 609,640 deaths, continuing a long-term decline in the overall cancer death rate.
Cancer statistics, 2023
CA A Cancer Journal for Clinicians · 2023 · Q1 · SJR 104.00 · FWCI 2007.41 · 16,754 citations · Open access
In 2023, the US is projected to see 1.96 million new cancer cases and 610,000 deaths, with notable incidence increases in prostate, breast, uterine corpus, liver cancers, and melanoma. Despite these rises, the overall cancer death rate continued its decline, falling 1.5% from 2019 to 2020, contributing to 3.8 million deaths averted since 1991.
Cancer statistics, 2016
CA A Cancer Journal for Clinicians · 2016 · Q1 · SJR 104.00 · FWCI 1605.01 · 16,170 citations
In 2016, the US is projected to see 1,685,210 new cancer cases and 595,690 deaths, with overall cancer incidence stable in women but declining 3.1% annually in men, largely due to fewer prostate cancer diagnoses.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
American Journal of Nephrology · 2017 · Q1 · SJR 1.00 · FWCI 255.21 · 15,288 citations · Open access
Immune checkpoint inhibitors (ICIs) like anti-CTLA-4 and anti-PD-1, while revolutionizing cancer treatment, can cause significant kidney toxicities, with recent studies suggesting incidence rates of 9.9-29%.
Cancer statistics, 2017
CA A Cancer Journal for Clinicians · 2017 · Q1 · SJR 104.00 · FWCI 1246.34 · 14,980 citations · Open access
In 2017, the US is projected to see 1,688,780 new cancer cases and 600,920 deaths, with incidence rates 20% higher in men and death rates 40% higher.
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · Q1 · SJR 18.00 · FWCI 362.66 · 12,708 citations · Open access
An anti-PD-1 antibody demonstrated objective responses in up to 28% of patients with advanced melanoma, non-small-cell lung cancer, or renal-cell cancer, with durable responses observed in a significant portion.
Cancer statistics, 2015
CA A Cancer Journal for Clinicians · 2015 · Q1 · SJR 104.00 · FWCI 1223.76 · 11,921 citations · Open access
In 2015, the US is projected to see 1,658,370 new cancer cases and 589,430 deaths, with significant progress shown in declining death rates over the past two decades.
Cancer statistics, 2013
CA A Cancer Journal for Clinicians · 2013 · Q1 · SJR 104.00 · FWCI 1139.58 · 11,904 citations · Open access
In 2013, the US is projected to see 1,660,290 new cancer cases and 580,350 deaths, with significant declines in mortality rates observed.
Cancer statistics, 2014
CA A Cancer Journal for Clinicians · 2014 · Q1 · SJR 104.00 · FWCI 1106.79 · 11,570 citations · Open access
In 2014, the US is projected to see 1,665,540 new cancer cases and 585,720 deaths, with cancer death rates having continuously declined for two decades.
Cancer statistics, 2012
CA A Cancer Journal for Clinicians · 2012 · Q1 · SJR 104.00 · FWCI 1011.08 · 10,720 citations
In 2012, the US is projected to see 1.64 million new cancer cases and 577,190 deaths, with overall cancer death rates continuing to decline.
Recently added
Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal
New England Journal of Medicine · 2026 · Q1 · SJR 18.00 · FWCI 7.43 · 2 citations
Beginning colonoscopy surveillance at 5 years after polyp removal is noninferior to the current 3-year recommendation for preventing colorectal cancer in high-risk patients, according to an interim analysis of a large trial.
Hallmarks of cancer—Then and now, and beyond
Cell · 2026 · Q1 · SJR 24.00 · FWCI 743.47 · 200 citations · Open access
This review synthesizes the evolution of the 'hallmarks of cancer' concept over 25 years, proposing that mechanism-guided co-targeting of these hallmarks offers impactful new therapeutic strategies.
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
The Lancet · 2025 · FWCI 317.08 · 752 citations
Global DALYs rose 6.1% (2.64B to 2.80B) from 2010-2023, but age-standardized rates fell 12.6%, indicating long-term health improvements. Communicable, maternal, neonatal, and nutritional (CMNN) disease burden significantly decreased (25.8% rate reduction), while non-communicable diseases (NCDs) increased (4.1% rate reduction, but total DALYs up 24%). High systolic blood pressure, air pollution, and diabetes are top risk factors.
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
The Lancet · 2024 · FWCI 846.15 · 4,581 citations · Open access
Global age-standardised DALY rates decreased 14.2% from 2010-2019, but reversed with a 4.1% increase in 2020 and 7.2% in 2021 due to COVID-19, which became the leading cause of DALYs in 2021.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians · 2024 · Q1 · SJR 104.00 · FWCI 4333.94 · 23,693 citations · Open access
In 2022, nearly 20 million new cancer cases and 9.7 million deaths were estimated globally, with lung cancer being the most frequent and deadliest. These figures highlight a lifetime risk of approximately 1 in 5 for developing cancer.
Cancer statistics, 2024
CA A Cancer Journal for Clinicians · 2024 · Q1 · SJR 104.00 · FWCI 1688.25 · 9,112 citations · Open access
In 2024, the US is projected to see 2,001,140 new cancer cases and 611,720 deaths, with mortality declining overall since 1991 due to prevention and treatment advances. However, incidence is rising for several cancers, including breast, pancreas, prostate, and colorectal cancer in younger adults.
American Medical Society of Sports Medicine Position Statement: Mononucleosis and Athletic Participation
Clinical Journal of Sport Medicine · 2023 · Q2 · FWCI 1.44 · 7 citations
The American Medical Society for Sports Medicine (AMSSM) has updated its position statement on infectious mononucleosis (IM) in athletes, providing evidence-based guidance on return-to-sport (RTS) decisions, particularly concerning the risk of splenic rupture.
Colorectal cancer statistics, 2023
CA A Cancer Journal for Clinicians · 2023 · Q1 · SJR 104.00 · FWCI 366.15 · 3,826 citations · Open access
Colorectal cancer (CRC) incidence is rising in younger adults, with 20% of new cases in those under 55 by 2019, up from 11% in 1995. This trend is reversing earlier progress in early-stage diagnosis, with 60% of cases diagnosed at advanced stages in 2019.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 23 | 376 |
| Ca-A Cancer Journal for Clinicians | Q1 | 104.00 | 236 | 21 | 39 |
| Science | Q1 | 10.00 | 1433 | 5 | 268 |
| International Journal of Cancer | Q1 | 1.00 | 275 | 3 | 5 |
| Cancer Research | Q1 | 4.00 | 522 | 2 | 6 |
| Cell | Q1 | 24.00 | 956 | 1 | 9 |
| Gut | Q1 | 8.00 | 385 | 1 | 15 |
| Nucleic Acids Research | Q1 | 8.00 | 714 | 1 | 43 |
Every journal in Oncology (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app